HPB : the official journal of the International Hepato Pancreato Biliary Association · 2025
Piperacillin-tazobactam versus cefoxitin as perioperative prophylaxis for pancreatoduodenectomy: real world evidence from the EPIC Cosmos database.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tsilimigras Diamantis I, Woldesenbet Selamawit, Moris Dimitrios, Zindani Shahzaib, Cloyd Jordan M, Dillhoff Mary, Tsai Susan, Pawlik Timothy M
Аннотация
BACKGROUND: Antimicrobial prophylaxis with piperacillin-tazobactam was recently demonstrated to reduce the incidence of surgical site infections (SSI) and pancreatic fistula following open pancreatoduodenectomy (PD) compared with cefoxitin. Larger scale, real-world data to confirm effectiveness of piperacillin-tazobactam are lacking.
METHODS: Patients undergoing open PD between 2016 and 2024 were identified in the EPIC Cosmos database. Exposure included perioperative administration of piperacillin-tazobactam versus cefoxitin as antimicrobial prophylaxis. Outcomes included development of SSI, pancreatic fistula, sepsis, multidrug-resistant (MDR) infections, and mortality (all 30-day outcomes).
RESULTS: Among 4039 patients who underwent open PD, 2496 (61.8 %) received perioperative cefoxitin, while 1543 (38.2 %) received piperacillin-tazobactam. Over time, piperacillin-tazobactam replaced cefoxitin as the predominant antimicrobial prophylaxis (p-trend <0.001). Patients who received piperacillin-tazobactam had a higher Charlson comorbidity index, more frequently had a history of diabetes, smoking and more frequently had preoperative biliary stent placed compared with individuals who received cefoxitin (all p < 0.05). Patients receiving piperacillin-tazobactam had a lower incidence of any SSI, superficial SSI, deep incisional/organ space SSI, pancreatic fistula and sepsis compared with cefoxitin (all p < 0.05). No difference was observed in 30-day MDR infections or mortality (p > 0.05).
CONCLUSIONS: The use of prophylactic piperacillin-tazobactam was associated with better perioperative outcomes compared with cefoxitin among patients undergoing open PD.
METHODS: Patients undergoing open PD between 2016 and 2024 were identified in the EPIC Cosmos database. Exposure included perioperative administration of piperacillin-tazobactam versus cefoxitin as antimicrobial prophylaxis. Outcomes included development of SSI, pancreatic fistula, sepsis, multidrug-resistant (MDR) infections, and mortality (all 30-day outcomes).
RESULTS: Among 4039 patients who underwent open PD, 2496 (61.8 %) received perioperative cefoxitin, while 1543 (38.2 %) received piperacillin-tazobactam. Over time, piperacillin-tazobactam replaced cefoxitin as the predominant antimicrobial prophylaxis (p-trend <0.001). Patients who received piperacillin-tazobactam had a higher Charlson comorbidity index, more frequently had a history of diabetes, smoking and more frequently had preoperative biliary stent placed compared with individuals who received cefoxitin (all p < 0.05). Patients receiving piperacillin-tazobactam had a lower incidence of any SSI, superficial SSI, deep incisional/organ space SSI, pancreatic fistula and sepsis compared with cefoxitin (all p < 0.05). No difference was observed in 30-day MDR infections or mortality (p > 0.05).
CONCLUSIONS: The use of prophylactic piperacillin-tazobactam was associated with better perioperative outcomes compared with cefoxitin among patients undergoing open PD.